Walleye Capital’s Ascendis Pharma A/S ASND Stock Holding History

Walleye Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.6M	Buy	126,005 +125,968	+340,454%	+$29.4M	0.12%	118
2026 Q1	$8.46K	Sell	37 -591	-94%	-$132K	﹤0.01%	4169
2025 Q4	$134K	Buy	+628	New	+$130K	﹤0.01%	3742
2025 Q3	–	Sell	-40,403	Closed	-$7.54M	–	4472
2025 Q2	$6.97M	Buy	40,403 +24,566	+155%	+$4M	0.03%	682
2025 Q1	$2.47M	Buy	+15,837	New	+$2.26M	0.01%	1273
2024 Q4	–	Sell	-1,014	Closed	-$151K	–	4830
2024 Q3	$151K	Buy	1,014 +458	+82%	+$61.9K	﹤0.01%	4181
2024 Q2	$75.8K	Buy	556 +527	+1,817%	+$71.7K	﹤0.01%	4817
2024 Q1	$4.38K	Sell	29 -1,133	-98%	-$162K	﹤0.01%	5175
2023 Q4	$146K	Buy	+1,162	New	+$116K	﹤0.01%	3856

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Walleye Capital's ASND Position: Q2 2026 in Review

Walleye Capital increased its Ascendis Pharma A/S (ASND) stake by 340,454% in Q2 2026, buying an estimated $29.4M and bringing the position to 126,005 shares worth $33.6M. The position accounts for 0.12% of the portfolio, ranked #118.

Walleye Capital first reported a position in ASND in Q4 2023 and has held it in 9 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Walleye Capital held 126,005 shares of Ascendis Pharma A/S worth $33.6M as of Q2 2026.
Walleye Capital bought 125,968 Ascendis Pharma A/S shares in Q2 2026, an estimated $29.4M.
Ascendis Pharma A/S made up 0.12% of Walleye Capital's portfolio in Q2 2026, its #118 holding.
Walleye Capital first reported a position in Ascendis Pharma A/S in Q4 2023 and has held it in 9 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.